Novonesis (Novozymes) B (WBO:NZYM) Total Liabilities : €4,247 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Novonesis (Novozymes) B Total Liabilities?

Novonesis (Novozymes) B's Total Liabilities for the quarter that ended in Jun. 2024 was €4,247 Mil.

Novonesis (Novozymes) B's quarterly Total Liabilities increased from Sep. 2023 (€1,826.12 Mil) to Dec. 2023 (€1,885.78 Mil) and increased from Dec. 2023 (€1,885.78 Mil) to Jun. 2024 (€4,247.20 Mil).

Novonesis (Novozymes) B's annual Total Liabilities increased from Dec. 2021 (€1,688.93 Mil) to Dec. 2022 (€1,846.08 Mil) and increased from Dec. 2022 (€1,846.08 Mil) to Dec. 2023 (€1,885.78 Mil).

Novonesis (Novozymes) B Total Liabilities Historical Data

The historical data trend for Novonesis (Novozymes) B's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Total Liabilities Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,198.79

1,245.20

1,688.93

1,846.08

1,885.78

Novonesis (Novozymes) B Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															2,013.36	1,937.54	1,826.12	1,885.78	4,247.20

Novonesis (Novozymes) B Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Novonesis (Novozymes) B's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	975.396	+	(612.477	+	297.911
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,886

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3813.341	-	1927.556
	=	1,886

Novonesis (Novozymes) B's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1630.6	+	(1072.5	+	1544.1
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,247

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	15252.2	-	11005
	=	4,247

Novonesis (Novozymes) B Total Liabilities Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (WBO:NZYM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK 0Q4U:UK NSIS B:Denmark NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines